Evidence map›Paper›PMID 38392063›Full record

Observational studyCurrent oncology (Toronto, Ont.)2024

Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications.

Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren

Open access · goldAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jari RadrosKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.ORCID 0000-0001-6434-4054
Anders KjellmanKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Lars HenningsohnKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Yngve ForslinKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Martin DelleKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Marianna HrebenyukKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Anna ThorKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.ORCID 0000-0003-2915-1761
Tomas ThielKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Maria HermannKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Per-Olof LundgrenKarolinska Institute C1:77, Karolinska University Hospital, 141 86 Stockholm, Sweden.ORCID 0000-0001-7976-6962
Karolinska University Hospital · SE

Funding

Grafströms Foundation for urological research x
6 · The paper itself

Abstract

The purpose of this study is to evaluate the treatment safety of thermal ablation compared to surgical treatment of T1a tumors (small renal masses) at a high-volume center. We conducted an observational single-center study based on data collected form the National Swedish Kidney Cancer Register (NSKCR) between 2015 and 2021. In total, 444 treatments of T1a tumors were included. Patients underwent surgery (partial or total nephrectomy) or ablative treatment-radiofrequency ablation (RFA) or microwave ablation (MWA). Patient characteristics were retrieved from patient records, and tumor complexity was estimated from pre-interventional CT scans. The odds ratio (OR) of suffering from a severe surgical complication following ablative treatment was estimated using a logistic regression model adjusted for age, BMI, ASA physical status classification, smoking status and RENAL nephrometry score. The frequency of severe surgical complications was 6.3% (16/256 treatments) after surgical intervention and 2.1% (4/188 treatments) following ablative treatment. Our primary hypothesis that ablative treatment is associated with a lower risk of severe surgical complications is supported by the results (OR 0.39; 0.19-0.79;

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansNephrectomyTreatment Outcomeablationinterventionkidney cancersurgerytreatment

Identifiers

PMID38392063
PMCPMC10888411
OpenAlexW4391598813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.